-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Assumes Vertex Pharmaceuticals at Overweight, Announces Price Target of $535

Benzinga·04/22/2025 11:51:35
Listen to the news
Cantor Fitzgerald analyst Carter Gould assumes Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight rating and announces Price Target of $535.